DUBLIN, Ohio--(BUSINESS WIRE)--July 12, 2006--Neoprobe Corporation (OTCBB:NEOP - News), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has initiated its Phase 2 multi-center clinical study of Lymphoseek(TM), a lymphatic tissue targeting agent being developed by the Company. Neoprobe was granted authorization by FDA earlier this year to commence patient enrollment in a Phase 2 multi-center clinical study to evaluate the safety and efficacy of Lymphoseek. Lymphoseek is intended to be used in biopsy procedures for the detection of lymph nodes in breast and melanoma cancers.
